BioCentury | Jul 6, 2020
Product Development

U.K. may be near 60M dose deal with Sanofi, GSK for second COVID-19 vaccine partnership

The U.K. is reportedly in talks to secure access to a second COVID-19 vaccine, this time from GlaxoSmithKline and Sanofi, as concerns grow over vaccine nationalism. The government has already partnered with AstraZeneca plc (LSE:AZN;...
BioCentury | Jun 30, 2020
Product Development

The U.K.’s push for COVID-19 master protocols pays off again with definitive data on lopinavir-ritonavir

The U.K.’s RECOVERY trial and broader strategy to encourage master protocol participation are proving their value again, this time with data showing that the lopinavir-ritonavir antiviral cocktail has no clinical benefit in hospitalized patients not...
BioCentury | Jun 30, 2020
Finance

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

Temasek takes stake in BioNTech   BioNTech SE (NASDAQ:BNTX) raised about $250 million from Temasek and other undisclosed investors in a private placement comprising $139 million in stock and $112 million in convertible notes. The...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...
BioCentury | Jun 26, 2020
Distillery Therapeutics

CDK12 identified as myotonic dystrophy target

DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Inhibiting the transcription elongation regulator CDK12 could treat DM1, which is caused by CTG repeat expansions in the DMPK gene that result in cellular accumulation of...
BioCentury | Jun 24, 2020
Politics, Policy & Law

U.K. accepting applications for subscription-based antibiotic pilot

NHS England is calling for biopharmas to apply for a contract to supply an antibiotic via the U.K.’s pilot subscription program, which will pay manufacturers a flat annual rate over 10 years for access to...
BioCentury | Jun 24, 2020
Deals

Data Bytes: Gilead’s 2020 cancer deals take on immuno-oncology from different angles

Gilead Sciences has partnered with or acquired five cancer companies in the past four months, with each deal anchored by a different approach to immuno-oncology. The biotech’s largest deal -- a $4.9 billion acquisition of...
BioCentury | Jun 24, 2020
Deals

Gilead gains access to tumor myeloid targets via Pionyr partnership

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...
BioCentury | Jun 24, 2020
Regulation

Myovant eyes third NDA for relugolix after endometriosis readout

An NDA submission for an endometriosis therapy could come early next year from Myovant, whose shares gained $2.49 (14%) to $19.90 Tuesday after the company posted positive data for relugolix in a second Phase III...
Items per page:
1 - 10 of 14807